Shares of abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $18.21 and traded as high as $18.31. abrdn Life Sciences Investors shares last traded at $18.28, with a volume of 92,971 shares trading hands.
abrdn Life Sciences Investors Stock Up 1.6%
The firm has a 50 day moving average price of $19.24 and a 200-day moving average price of $18.21.
abrdn Life Sciences Investors Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Monday, August 24th. This represents a $2.48 annualized dividend and a dividend yield of 13.6%.
Institutional Trading of abrdn Life Sciences Investors
A number of institutional investors have recently bought and sold shares of HQL. Ashton Thomas Securities LLC bought a new stake in abrdn Life Sciences Investors in the third quarter worth $242,000. Flagship Harbor Advisors LLC boosted its stake in abrdn Life Sciences Investors by 4.1% during the third quarter. Flagship Harbor Advisors LLC now owns 417,366 shares of the company’s stock worth $7,805,000 after buying an additional 16,601 shares during the period. Wedbush Securities Inc. increased its position in abrdn Life Sciences Investors by 21.1% during the third quarter. Wedbush Securities Inc. now owns 19,335 shares of the company’s stock valued at $362,000 after acquiring an additional 3,375 shares during the last quarter. Envestnet Asset Management Inc. increased its position in abrdn Life Sciences Investors by 111.3% during the second quarter. Envestnet Asset Management Inc. now owns 30,011 shares of the company’s stock valued at $601,000 after acquiring an additional 15,805 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in abrdn Life Sciences Investors during the second quarter valued at $287,000. 32.21% of the stock is currently owned by institutional investors.
abrdn Life Sciences Investors Company Profile
abrdn Life Sciences Investors is a publicly traded closed-end investment company listed on the New York Stock Exchange under the symbol HQL. The fund seeks long-term capital appreciation by investing in companies involved in the life sciences industry.
Its portfolio may include businesses across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related fields. The fund can invest in both publicly traded and privately held companies, providing shareholders with diversified exposure to innovative healthcare and life sciences businesses.
The fund was formerly known as Tekla Life Sciences Investors and adopted the abrdn name following the integration of Tekla’s investment management activities into abrdn.
Read More
- Five stocks we like better than abrdn Life Sciences Investors
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.
